Bifogade filer
Prolight receives new MicroFlex patent approval in the US
Prenumeration
Kalender
| Est. tid* | ||
| 2025-11-27 | 09:50 | Kvartalsrapport 2025-Q3 |
| 2025-08-28 | 09:50 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2025-06-24 | N/A | Årsstämma |
| 2025-05-30 | 09:50 | Kvartalsrapport 2025-Q1 |
| 2025-02-28 | - | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-28 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | Årsstämma |
| 2024-05-17 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-15 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-27 | - | Extra Bolagsstämma 2023 |
| 2023-11-27 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-29 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-21 | - | Bokslutskommuniké 2022 |
| 2022-11-30 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-08-04 | - | Extra Bolagsstämma 2022 |
| 2022-05-23 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-05-20 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-22 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-31 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-24 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-21 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2020-05-20 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-11-20 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-28 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-10 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2018-11-20 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-28 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-17 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2018-05-16 | - | Årsstämma |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
| 2017-11-23 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-25 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-22 | - | X-dag ordinarie utdelning PRLD 0.00 SEK |
| 2017-05-19 | - | Årsstämma |
| 2017-05-19 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prolight announces today that the US Patent and Trademark Office (USPTO), pursuant to the notice of allowance issued on March 26, has granted Prolight a patent for the analytical unit and reaction chamber for the company's point-of-care analysis system, MicroFlex, which is being developed by Prolight's partner TTP (The Technology Partnership plc).
This patent complements the patent portfolio for MicroFlex, which now consists of six registered patents (three in the US, two in the EU, and one in Sweden) and three patent applications that have advanced to the national phase and are now being pursued in various territories.
The patent, US Patent No. 12,285,760, is valid until May 2040 and provides protection for the unique technical composition of the MicroFlex analytical unit and reaction chamber.
“With this granted patent Prolight strengthens the technological protection and reinforces the long-term value of the Microflex platform,” said Ulf Bladin, CEO of Prolight.
For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com
About Us
Prolight Diagnostics AB develops innovative Point-of-Care (POC) systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood.
We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.